Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22918249 | 0.82 | LOXL2 (0.41) | LOXL2ALDH1A1GAAHSD17B10KIF11 | |
| SCHEMBL29852265 | 0.82 | LOXL2 (0.41) | LOXL2ALDH1A1GAAHSD17B10KIF11 | |
| SCHEMBL22918320 | 0.82 | PRSS1 (0.41) | LOXL2HSD17B10LOX | |
| SCHEMBL22918299 | 0.76 | NR1H2 (0.46) | LOXL2NR1H2NR1H3 | |
| SCHEMBL29852396 | 0.76 | NR1H2 (0.46) | LOXL2NR1H2NR1H3 | |
| SCHEMBL29852658 | 0.72 | KMT2A (0.40) | LOXL2ALDH1A1KIF11 | |
| SCHEMBL22918327 | 0.72 | KMT2A (0.40) | LOXL2ALDH1A1KIF11 | |
| SCHEMBL22918247 | 0.71 | AOC3 (0.39) | LOXL2ALDH1A1 | |
| SCHEMBL1294652 | 0.71 | LOXL2 (0.42) | LOXL2GRM2GRM3ALDH1A1GAA | |
| SCHEMBL1294657 | 0.71 | LOXL2 (0.42) | LOXL2GRM2GRM3ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251036-A1 | DIFLUOROHALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES, METHODS OF PREPARATION, AND USES THEREOF | PHARMAXIS LTD. (AU) | 2022-08-11 | — | — | US | disclosed |
| WO-2021012014-A1 | DIFLUOROHALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES, METHODS OF PREPARATION, AND USES THEREOF | PHARMAXIS LTD. (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251036-A1 | DIFLUOROHALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES, METHODS OF PREPARATION, AND USES THEREOF | DAO, SMOX, PIGO | LOXL2 27/4885GRM2 4491/4885GRM3 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.